RxDoctor Payments Data

Giang Tran, PA

Physician Assistant · Dallas, TXNPI 1649915422

Payments from drug & device makers

$958in general payments, 2019–2025

Across 35 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$315
  • Novartis$308
  • E.r. Squibb & Sons, L.L.C.$92
  • Johnson & Johnson$39
  • Boston Scientific$30
  • Kiniksa Pharmaceuticals International, PLC$23
  • plus $151 from 8 others

What the payments were for

  • Food & beverage$92697%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$958 in reported general payments places this provider in the 60th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$116,893
Medicare patients
591
Services billed
1,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$109,209
EntrestoSacubitril/Valsartan45$58,584
XareltoRivaroxaban57$45,815
FarxigaDapagliflozin Propanediol35$42,258
Repatha SyringeEvolocumab14$8,563
Metoprolol Succinate171$1,941
Ranolazine ErRanolazine12$1,632
Losartan Potassium126$1,270
Atorvastatin Calcium136$1,169
Carvedilol123$1,037
Spironolactone112$862
Furosemide155$812
Midodrine Hcl12$783
Rosuvastatin Calcium47$737
Metoprolol Tartrate102$730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$308$58,58445 claims
Johnson & JohnsonXarelto$39$45,81557 claims
AstraZenecaFarxiga$19$42,25835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →